MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.gastro.2022.08.045

Медицинская библиотека · Gastroenterology · 2022

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.

Grunvald Eduardo, Shah Raj, Hernaez Ruben, Chandar Apoorva Krishna, Pickett-Blakely Octavia, Teigen Levi M, Harindhanavudhi Tasma, Sultan Shahnaz, Singh Siddharth, Davitkov Perica, AGA Clinical Guidelines Committee

Клинические рекомендацииСтатьяПеревод в очереди

Аннотация

BACKGROUND & AIMS: Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity.

METHODS

A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis of the following agents: semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone-bupropion ER, orlistat, phentermine, diethylpropion, and Gelesis100 oral superabsorbent hydrogel. The guideline panel used the evidence-to-decision framework to develop recommendations for the pharmacological management of obesity and provided implementation considerations for clinical practice.

RESULTS

The guideline panel made 9 recommendations. The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions. The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity. The guideline panel suggested against the use of orlistat. The panel identified the use of Gelesis100 oral superabsorbent hydrogel as a knowledge gap.

CONCLUSIONS

In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options.

Для цитирования: Grunvald Eduardo, Shah Raj, Hernaez Ruben, Chandar Apoorva Krishna, Pickett-Blakely Octavia, Teigen Levi M, Harindhanavudhi Tasma, Sultan Shahnaz, Singh Siddharth, Davitkov Perica, AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.. Gastroenterology. 2022. DOI: 10.1053/j.gastro.2022.08.045.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.